Abstract
The use of intravitreal injections of anti-Vascular Endothelial Growth Factor (anti-VEGF) has been used for a broad spectrum of ocular pathologic entities. Although the dose of anti-VEGF agents used for treating eye disease is minute compared with that used intravenously, intraocular administration can lead to systemic absorption and reduce serum VEGF levels. Several systemic side effects, such as hypertension and cardiovascular complications have been rarely reported in the literature.
Renal complications of intravenous administration of anti-VEGF, are well known and include a variety of renal pathological damage which can induce proteinuria and hypertension.
We describe herein, 2 cases of diabetic patients with preexisting kidney disease who presented severe reduction of their renal function after intraocular administration of anti-VEGF. Although a cause –effect correlation cannot be established unless further studies are performed, we believe that pretreatment counseling should include a discussion outlining the possible risk of aggravating of the renal function in patients with kidney disease. Close cooperation with the patient’s nephrologist and close monitoring of the patient may be required, in such cases, in order to monitor the renal function before and after the intravitreal administration of anti-VEGF.
Keywords: Diabetic retinopathy, intravitreal anti-vascular endothelial growth factor, renal damage.
Current Drug Safety
Title:Renal Injury Following Intravitreal Anti-VEGF Administration in Diabetic Patients with Proliferative Diabetic Retinopathy and Chronic Kidney Disease - A Possible Side Effect?
Volume: 9 Issue: 2
Author(s): Ilias Georgalas, Dimitris Papaconstantinou, Kostas Papadopoulos, Dionisis Pagoulatos, Dimitris Karagiannis and Chryssanthi Koutsandrea
Affiliation:
Keywords: Diabetic retinopathy, intravitreal anti-vascular endothelial growth factor, renal damage.
Abstract: The use of intravitreal injections of anti-Vascular Endothelial Growth Factor (anti-VEGF) has been used for a broad spectrum of ocular pathologic entities. Although the dose of anti-VEGF agents used for treating eye disease is minute compared with that used intravenously, intraocular administration can lead to systemic absorption and reduce serum VEGF levels. Several systemic side effects, such as hypertension and cardiovascular complications have been rarely reported in the literature.
Renal complications of intravenous administration of anti-VEGF, are well known and include a variety of renal pathological damage which can induce proteinuria and hypertension.
We describe herein, 2 cases of diabetic patients with preexisting kidney disease who presented severe reduction of their renal function after intraocular administration of anti-VEGF. Although a cause –effect correlation cannot be established unless further studies are performed, we believe that pretreatment counseling should include a discussion outlining the possible risk of aggravating of the renal function in patients with kidney disease. Close cooperation with the patient’s nephrologist and close monitoring of the patient may be required, in such cases, in order to monitor the renal function before and after the intravitreal administration of anti-VEGF.
Export Options
About this article
Cite this article as:
Georgalas Ilias, Papaconstantinou Dimitris, Papadopoulos Kostas, Pagoulatos Dionisis, Karagiannis Dimitris and Koutsandrea Chryssanthi, Renal Injury Following Intravitreal Anti-VEGF Administration in Diabetic Patients with Proliferative Diabetic Retinopathy and Chronic Kidney Disease - A Possible Side Effect?, Current Drug Safety 2014; 9 (2) . https://dx.doi.org/10.2174/1574886309666140211113635
DOI https://dx.doi.org/10.2174/1574886309666140211113635 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
EDITORIAL [Hot Topic: Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Ophthalmic Conditions (Guest Editor: Michael W. Stewart)]
Current Drug Therapy Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets Ocular Vascular Involvement in the Rheumatic Diseases
Current Rheumatology Reviews The Role of Adipocytokines in Atherogenesis and Atheroprogression
Current Drug Targets Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology Traumatic Spinal Cord Injury Alters Angiogenic Factors and TGF-Beta1 that may Affect Vascular Recovery
Current Neurovascular Research CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Current Pharmaceutical Design Recent Advances in Intraocular Drug Delivery Systems
Recent Patents on Drug Delivery & Formulation Subthreshold Diode Micropulse Laser Photocoagulation (SDM) as Invisible Retinal Phototherapy for Diabetic Macular Edema: A Review
Current Diabetes Reviews Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide
Current Pharmaceutical Design The Role of microRNAs in the Development of Type 2 Diabetes Complications
Current Pharmaceutical Design Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery ANN Classification and Modified Otsu Labeling on Retinal Blood Vessels
Current Signal Transduction Therapy Pharmacogenomics of Open-Angle Glaucoma
Current Pharmacogenomics and Personalized Medicine Measurement and Mapping of Retinal Leakage and Retinal Thickness - Surrogate Outcomes for the Initial Stages of Diabetic Retinopathy
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Platelet Resistance to the Anti-Aggregating Agents in the Insulin Resistant States
Current Diabetes Reviews Anti-Tumor Necrosis Factor Blocking Agents in the Treatment of Systemic Vasculitis
Current Immunology Reviews (Discontinued) Impact of Omega-3 and Trans Fatty Acids on Vascular Remodeling:Opposing Roles in Cardiovascular Health
Current Enzyme Inhibition Directed Differentiation of Pluripotent Cells Towards Therapeutic Stem Cells
Recent Patents on Regenerative Medicine